With the signing of a drug discovery collaboration for broad-spectrum small molecule antibiotics between RQx Pharmaceuticals and Roche's Genentech that's worth up to $111 million plus royalties, Avalon Ventures has signed its third deal this year that allows the San Diego-based venture capital firm to exit an early-stage investment.
Two of Avalon's transactions during the first six weeks of 2013 have been with Genentech, which has been on the lookout for early-stage technology. Genentech agreed to pay up to $187.5 million in upfront and milestone payments at the end of January to access the central nervous system-focused platform developed by the Avalon portfolio company Afraxis of San Diego (
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?